Dr. Gordon on Clinical Trials in Hodgkin Lymphoma

Leo I. Gordon, MD
Published: Thursday, Nov 30, 2017



Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Data suggests that the immune system and the use of checkpoint inhibitors may play an important role in Hodgkin lymphoma, says Gordon. These novel agents take the brakes off the immune system so it can attack the disease.

According to Gordon, there are trials comparing ABVD [adriamycin, bleomycin, vinblastine, dacarbazine] with other regimens, but ABVD remains the standard. However, the drug bleomycin causes pulmonary toxicity, especially in patients who are a little bit older with a smoking history.
 


Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Data suggests that the immune system and the use of checkpoint inhibitors may play an important role in Hodgkin lymphoma, says Gordon. These novel agents take the brakes off the immune system so it can attack the disease.

According to Gordon, there are trials comparing ABVD [adriamycin, bleomycin, vinblastine, dacarbazine] with other regimens, but ABVD remains the standard. However, the drug bleomycin causes pulmonary toxicity, especially in patients who are a little bit older with a smoking history.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x